Wednesday, July 8, 2026

Drug profile · INN

vancomycin

vancomycin (VANCOCIN) is a peptidoglycan inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: intravenous, oral. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 20
Pipeline programs 15
News articles 0
Drug details — vancomycin
US status
approved
Class
Route
INTRAVENOUS, ORAL
Patents
20
Programs
15
Data quality
0.84

Quick answer

vancomycin (VANCOCIN) is a peptidoglycan inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: intravenous, oral. Current US regulatory status: approved.

Key facts

INN vancomycin
Brand VANCOCIN
Mechanism Peptidoglycan inhibitor
Target Peptidoglycan
Route INTRAVENOUS, ORAL
Formulation SOLUTION

Mechanism of action

Peptidoglycan inhibitor

Primary target: Peptidoglycan

Approval history

Authority Status Date
FDA approved
TGA approved

Pipeline programs

  1. APHP210089 Phase 3 · PARItec · Patients hospitalized for allogeneic hematopoietic stem cell
  2. APHP220763 Phase 3 · PARItec · Catheter related bloodstream infections due to Staphylococcu
  3. MGT-RPGR-022 Phase 3 · Janssen-Cilag International N.V · X-Linked Retinitis Pigmentosa caused by mutations in the RPG
  4. Vedolizumab-3041 Phase 3 · Takeda · Active Chronic Pouchitis
  5. APHP221107 Phase 2 · PARItec · Healthy volunteers : Healthy adults with no history of gast
  6. VANCOMYCIN , MaaT013 Phase 2 · Anaxis Pharma · Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
  7. Vancomycin Phase 2 · Cardiff Oncology · Late Onset Neonatal Sepsis
  8. Vancomycin Pre-Treatment Phase 2 · Seres Therapeutics · Ulcerative Colitis

Related & competitor drugs

  1. dalbavancin hydrochloride Peptidoglycan inhibitor
  2. vancomycin hydrochloride Peptidoglycan inhibitor
  3. amdinocillin Bacterial penicillin-binding protein 2 inhibitor
  4. oritavancin diphosphate Peptidoglycan inhibitor
  5. pivmecillinam hydrochloride Bacterial penicillin-binding protein 2 inhibitor
  1. US 12409197

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11918612

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11701394

    Compositions and methods for treating cholestatic disease

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11666612

    Network-based microbial compositions and methods

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11464812

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11458174

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11458173

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11389490

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11266699

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10973861

    Compositions and methods

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10967011

    Compositions and methods

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10881696

    Network-based microbial compositions and methods

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10864235

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10258655

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10076546

    Network-based microbial compositions and methods

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10064901

    Compositions and methods

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 9855303

    Compositions and methods

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 9585921

    Compositions and methods

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 9533014

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is vancomycin?

vancomycin (VANCOCIN) is a peptidoglycan inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: intravenous, oral. Current US regulatory status: approved.

What is the brand name for vancomycin?

VANCOCIN is a marketed brand name for vancomycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of vancomycin?

vancomycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.